SCYNEXIS, Inc. announced on December 18, 2024, that it had completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247. SCY-247 is the company’s second-generation triterpenoid antifungal, currently in development for the treatment of severe invasive fungal infections.
This initiation marks a significant step in advancing SCY-247, which has demonstrated potent activity in preclinical studies against a broad range of invasive fungal infections. The compound is being developed to address the growing threat of drug-resistant fungal pathogens.
The progression of SCY-247 into clinical trials underscores SCYNEXIS's commitment to expanding its proprietary fungerp platform. This milestone is crucial for the company's strategy to develop innovative medicines for difficult-to-treat infections.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.